Who Clears the Most FDA 510(k) Devices? 175K Records by Country and Applicant

Executive Summary

The FDA 510(k) premarket notification pathway is the workhorse of US medical device regulation — roughly 3,000 to 3,400 devices are cleared each year. But who are the companies behind those clearances, and where are they located?

Our analysis of the complete FDA 510(k) clearance database — 175,149 records spanning 1976 to June 2026, from 34,386 unique applicants across 60+ countries — reveals a market that has fundamentally shifted over the past decade. Foreign-based applicants now account for the majority of 510(k) clearances every single year since 2021, a reversal from the 80%+ US dominance that persisted through the 2010s. China alone contributes more clearances than any other non-US country, with 5,520 total (3.2% of all clearances, 19.1% of all non-US clearances).

At the same time, the market remains remarkably fragmented. The top 10 applicants hold just 3.3% of all clearances, and the top 50 hold 9.6%. No single company dominates — even Abbott Laboratories, the most prolific applicant with 883 clearances over four decades, represents just 0.5% of the total.

This article quantifies the geographic shift, identifies the most active applicants and specialties, and traces the year-over-year trend that is reshaping who brings medical devices to the US market.

Data Source and Methodology

All statistics in this article are derived from our direct analysis of the FDA 510(k) clearance database (public dataset, extracted June 2026), which covers all 510(k) clearances from the program's inception in 1976 through the date of extraction. The dataset includes 175,149 clearance records with applicant name, country, product code, medical specialty, decision date, and clearance type.

Country codes were mapped to standard ISO country names. Where an applicant's country code is blank (1,439 records, 0.8%), those records are excluded from country-level analyses. Percentages are calculated against the relevant denominator (total records unless otherwise noted).

The US-to-Foreign Shift: A Decade in Numbers

The most striking trend in the 510(k) database is the erosion of US-based applicant share. In 2012, US applicants accounted for 81.9% of clearances. By 2025, that figure had fallen to 47.8%. Foreign applicants have held the majority every year since 2021.

The inflection point came in 2015–2016, when non-US share jumped from 33.4% to 38.1% in a single year. Since then, the foreign share has grown steadily. The shift is not driven by a decline in US submissions — US-based clearances have held relatively steady at 1,400–1,700 per year — but rather by a surge in foreign applicants entering the US market.

Key context: The overall annual clearance volume has remained in a stable band of ~2,900–3,400 for over a decade. The composition of that volume has changed dramatically, even as the total has not.

Non-US Clearance Geography: Who Leads Abroad

Among the 28,863 non-US clearances, the top 10 source countries account for 75.3% of all foreign-origin clearances. China is the clear leader.

Several patterns stand out:

• China's breadth. With 5,520 clearances, China has more than double the next closest country (Germany, 2,437). China's clearances span virtually every medical specialty — General Hospital (20.3%), General & Plastic Surgery (18.2%), Cardiovascular (14.6%), and Radiology (11.4%) are the top four.
• Country specialization. Germany leads in Dental (20.4% of its clearances). South Korea also concentrates heavily in Dental (25.6%) and Radiology (24.7%). Canada emphasizes Radiology (15.2%) and Neurology (10.0%). Taiwan distributes more evenly across General Hospital, Physical Medicine, Clinical Chemistry, and Cardiovascular.
• Malaysia's scale. With 1,325 clearances, Malaysia exceeds Japan (1,236) — driven largely by glove and PPE manufacturers like Wembley Rubber Products. This is an artifact of the COVID-era surge in barrier-product clearances.

Top 510(k) Applicants: A Fragmented Market

Despite the geographic shift, the 510(k) market remains extremely fragmented across applicants.

Cumulative concentration:

• Top 10 applicants: 5,769 clearances (3.3% of total)
• Top 20 applicants: 9,256 clearances (5.3%)
• Top 50 applicants: 16,829 clearances (9.6%)

This is a market with no meaningful concentration at the applicant level. The top applicant (Abbott) holds barely half a percent of all clearances. The 34,386 unique applicants reflect decades of turnover, M&A (e.g., C.R. Bard is now part of BD, Biomet merged into Zimmer Biomet), and name changes that fragment the count.

Recent Leaders (2020–2026)

When looking at the most recent period, the applicant rankings shift notably:

Key observations:

• Shanghai United Imaging appears at #9 with 60 clearances in under seven years — a pace that underscores the Chinese medical imaging manufacturer's aggressive US market entry.
• Medacta International (Switzerland) ranks #3 with 100 clearances, reflecting the orthopedic company's rapid expansion.
• Canon Medical Systems (Japan, #5 with 72) reflects the continued strength of Japanese imaging manufacturers.
• Intuitive Surgical (#6 with 65) shows that even a company focused on a single robotic platform generates substantial clearance volume through instruments and accessories.

Leading Non-US Applicants (All Time)

Among applicants headquartered outside the United States:

Medical Specialty Breakdown

The 510(k) database spans 20+ medical specialties. The top five account for nearly half of all clearances:

Cardiovascular has held the #1 spot consistently, driven by the volume of catheters, stents, grafts, and implantable accessories that require clearance. The breadth of Cardiovascular is noteworthy — it encompasses both high-volume commodity devices and innovative technologies.

Clearance Type Distribution

The vast majority of 510(k) clearances are Traditional submissions:

Special 510(k)s — used when a manufacturer modifies its own legally marketed device — account for roughly 9% of clearances. The Abbreviated pathway, which relies on conformity to FDA-recognized standards, remains a small share at 1.5%.

Annual Clearance Volume: Stable but Shifting

Total annual 510(k) clearances have stayed in a relatively narrow band:

The peak year in the past decade was 2023 with 3,346 clearances. The 2025 figure of 3,225 suggests continued stability. The FDA CDRH has noted that it processes roughly 3,000 510(k) submissions annually, a rate that has been "largely stable since 2007" according to the agency.

What This Means for Industry

Three implications stand out from this analysis:

1. The US market is no longer a US-only game. With foreign applicants exceeding 50% of clearances since 2021, any competitive analysis that ignores non-US manufacturers is incomplete. Chinese, German, Korean, and Taiwanese companies are not just entering — they are establishing sustained clearance programs across multiple specialties.

2. Fragmentation is the norm. The absence of concentration at the applicant level means the 510(k) pathway serves a huge ecosystem of companies — from global multinationals to single-product startups. This fragmentation also means FDA reviewers face enormous variety in submission quality and complexity.

3. China's trajectory is structural, not cyclical. China leads all non-US countries by a wide margin and its clearances span virtually every medical specialty. Companies like Shenzhen Mindray and Shanghai United Imaging are building multi-decade US regulatory footprints. For incumbent US and European manufacturers, this represents both competitive pressure and potential partnership opportunities.

Data source: FDA 510(k) clearance database; analysis by MedDeviceGuide, run date 2026-06-10. Analysis sample: complete database extract, 175,149 clearance records from 1976 through June 2026.